169463-46-1

Basic information

• Product Name: 1H-Indole-2-carboxylic acid, 5-cyano-3-methyl-
• CAS NO: 169463-46-1
• Molecular Formula: C11H8N2O2
• Molecular Weight: 200.197
• Mol File: 169463-46-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 1H-Indole-2-carboxylic acid, 5-cyano-3-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indole-2-carboxylic acid, 5-cyano-3-methyl-(169463-46-1)
• EPA Substance Registry System: 1H-Indole-2-carboxylic acid, 5-cyano-3-methyl-(169463-46-1)

Safety Data

• Hazardous Substances Data: 169463-46-1(Hazardous Substances Data)

Usage

Structure

A derivative of indole, a heterocyclic compound with a benzene ring fused to a pyrrole ring.

Substituents

A cyano group at position 5 and a methyl group at position 3 of the indole ring.

Biological activity

Potential anti-inflammatory, antimicrobial, and anti-tumor properties.

Applications

Commonly used in the synthesis of pharmaceuticals and agrochemicals due to its potential biological activity.

Importance

A valuable building block for drug discovery and development.

Upstream product

• 194163-29-6 3-(5-Cyano-2-nitro-phenyl)-2-oxo-butyric acid ethyl ester 
• 169463-42-7 (5-cyano-2-nitro-phenyl)-pyruvic acid ethyl ester 
• 169463-45-0 ethyl-3-methyl-5-cyanoindole-2-carboxylate 
• 96784-54-2 3-methyl-4-nitrobenzonitrile 
• 3113-71-1 3-methyl-4-nitrobenzoic acid 

Downstream Products

• 169464-34-0 7-[(5-Cyano-3-methyl-1H-indole-2-carbonyl)-amino]-heptanoic acid methyl ester 

Relevant articles and documents

Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists

The use of 5,6-bicyclic amidines as arginine surrogates in the design of a novel class of potent platelet glycoprotein IIb-IIIa receptor (GPIIb-IIIa) antagonists is described. The additional conformational restriction offered by the bicyclic nucleus results in 20-400-fold increases in potency compared to the freely flexible, acyclic benzamidine counterpart. The design, synthesis, structure-activity relationships (SAR), and in vitro activity of this novel class of GPIIb-IIIa antagonists are presented.